Dear Friends and Colleagues,
As you know, the CNADC is scheduled to move to new and larger headquarters in November. The move will help expand successful programs and initiate new ones. As part of these developments, I am delighted to announce changes that will invigorate the CNADC and allow me to focus more fully on program development.
1) Emily Rogalski, PhD has agreed to serve as Associate Director of the CNADC. She will play a key role in the integration of CNADC components while continuing to pursue her highly productive lines of research on imaging, primary progressive aphasia and SuperAging.
2) Robert Vassar, PhD has agreed to serve as Principal Investigator (PI) of the Alzheimer’s Disease Core Center (P30), which I founded in 1996. The shift will occur on October 1, 2018, or soon thereafter. Dr. Vassar is a world-renowned investigator in the cellular and molecular biology of Alzheimer’s disease and will enrich our basic science portfolio.
3) Sandra Weintraub, PhD the founding Clinical Core Leader of the Alzheimer’s Disease Core Center (NIA P30), will maintain this responsibility and also serve as Associate Director of the P30. Dr. Weintraub is internationally recognized for her work on the neuropsychology of neurocognitive disorders.
I will continue to serve as Director of the CNADC. I am adding a chart to illustrate the new administrative landscape. Please join me in thanking and congratulating Emily, Bob and Sandy for agreeing to take on these key leadership positions. They will collectively promote the CNADC’s multidepartmental missions to clarify the biology of brain aging and dementia, explore the cognitive networks affected by the underlying diseases, and develop interventions that make our patients the beneficiaries of related developments.
Marsel Mesulam, MD